Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma - Related Studies

Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

This study has been completed.

Study NCT00033332. Last updated on October 8, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Additional conditions recognized in this trial
		Multiple Myeloma
		Neoplasms, Plasma Cell

2	More general conditions related to this trial
		Blood Protein Disorders
		Cardiovascular Diseases
		Hematologic Diseases
		Hemorrhagic Disorders
		Hemostatic Disorders
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Paraproteinemias
		Vascular Diseases

3	Interventions listed in this trial
		dexamethasone
		pamidronate disodium
		thalidomide
		zoledronic acid

4	Additional drug interventions recognized in this trial
		Dexamethasone acetate
		Pamidronate

5	More general drug interventions related to this trial
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Anti-Bacterial Agents
		Anti-Infective Agents
		Anti-Inflammatory Agents
		Antiemetics
		Antineoplastic Agents
		Antineoplastic Agents, Hormonal
		Autonomic Agents
		Bone Density Conservation Agents
		Central Nervous System Agents
		Gastrointestinal Agents
		Glucocorticoids
		Growth Inhibitors
		Growth Substances
		Hormones
		Hormones, Hormone Substitutes, and Hormone Antagonists
		Immunologic Factors
		Immunosuppressive Agents
		Leprostatic Agents
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		Eastern Cooperative Oncology Group
		National Cancer Institute (NCI)